School of Medicine, Ningbo University, Ningbo, Zhejiang, China.
Department of Otolaryngology Head and Neck Surgery, Ningbo Medical Center (Ningbo Lihuili Hospital), The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China.
Otol Neurotol. 2020 Jul;41(6):782-790. doi: 10.1097/MAO.0000000000002628.
To investigate the effectiveness of basic fibroblast growth factor (bFGF) versus placebo or no intervention in the treatment of tympanic membrane (TM) perforations from randomized controlled trials (RCTs), prospective and retrospective studies.
PubMed, EMBASE, and Cochrane databases were screened from their inceptions to June 2019.
Inclusion criteria: 1) English language; 2) observational (retrospective or prospective) or treatment (RCT) studies; 3) reported the outcomes on the application of bFGF in adult or pediatric population.
Number of patients, cause of TM perforation, perforation size, treatment, mean age, follow-up time, sex, closure rate, healing time, mean air-bone gap improvement.
A total of 14 studies were included, including seven RCTs and seven non-RCTs with a total of 1,072 participants. The odds ratio for closure rate of bFGF treatment was 7.33 (95% confidence interval [CI], 4.65 to 11.53; p < 0.01; I = 44%) and the standardized mean difference (SMD) for healing time was -5.89 (95% CI: -7.85 to -3.93, p < 0.01, I = 98%), suggesting bFGF application has a significant effect on closure of TM perforations. However, no significant change in hearing (SMD: 0.08, 95% CI: -0.11 to 0.27, p = 0.39, I = 0%) was seen as a result of bFGF treatment.
Our meta-analysis has revealed that the application of bFGF can significantly enhance the closure rate as well as shorten the healing time for TM perforations. In terms of hearing, there is as yet no evidence that bFGF has a significant effect. Given its ease, availability, and safety, bFGF can be used effectively for TM repair.
研究碱性成纤维细胞生长因子(bFGF)与安慰剂或不干预治疗鼓膜穿孔的疗效,纳入随机对照试验(RCT)、前瞻性和回顾性研究。
从建库至 2019 年 6 月,检索 PubMed、EMBASE 和 Cochrane 数据库。
纳入标准:1)英语语言;2)观察性(回顾性或前瞻性)或治疗(RCT)研究;3)报告 bFGF 应用于成人或儿科人群的结果。
1)无对照组的研究;2)动物研究、体外研究、综述研究和病例报告。
患者数量、鼓膜穿孔原因、穿孔大小、治疗、平均年龄、随访时间、性别、闭合率、愈合时间、气骨导差平均改善。
共纳入 14 项研究,包括 7 项 RCT 和 7 项非 RCT,共 1072 名参与者。bFGF 治疗的闭合率比值比为 7.33(95%置信区间[CI]:4.65 至 11.53;p<0.01;I²=44%),愈合时间的标准化均数差(SMD)为-5.89(95%CI:-7.85 至-3.93,p<0.01,I²=98%),提示 bFGF 应用对鼓膜穿孔的闭合有显著效果。然而,bFGF 治疗对听力无显著影响(SMD:0.08,95%CI:-0.11 至 0.27,p=0.39,I²=0%)。
我们的荟萃分析表明,bFGF 的应用可显著提高鼓膜穿孔的闭合率并缩短愈合时间。在听力方面,目前尚无证据表明 bFGF 有显著效果。鉴于其简便、易得和安全性,bFGF 可有效用于鼓膜修复。